Liver cavernous hemangioma
MONDO:0006267A hemangioma with cavernous vascular spaces arising from the liver. It is the most frequent benign tumor of the liver and usually affects young females.
Also known as: cavernous hemangioma of liver, liver cavernous hemangioma
1788 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Custom-Made cancer vaccine enters early human testing
⭐️ VACCINE ⭐️ Not yet recruitingThis study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …
Phase: EARLY_PHASE1 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:33 UTC
-
New drug DS1025a takes on advanced solid tumors in first human trial
Disease control Not yet recruitingThis trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Bicycle therapies offer continued hope for advanced tumors
Disease control Not yet recruitingThis trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…
Phase: PHASE2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New antibody drug targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingThis study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New cancer drug candidate SHR-4685 enters first human tests
Disease control Not yet recruitingThis early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…
Phase: PHASE1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug XYA02 takes on tough cancers in first human trial
Disease control Not yet recruitingThis study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…
Phase: PHASE1, PHASE2 • Sponsor: XYone Therapeutics, Inc • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Bile acid pill may turbocharge liver regrowth after transplant
Disease control Not yet recruitingThis trial tests whether ursodeoxycholic acid (UDCA), a bile acid supplement, can speed up liver regeneration in adults receiving a living-donor liver transplant. Participants take UDCA or a placebo starting at least 10 days before surgery and continuing for 10 days after. Resear…
Phase: NA • Sponsor: Institute of Liver and Biliary Sciences, India • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Extended look at gotistobart: could Long-Term use improve survival in advanced cancers?
Disease control Not yet recruitingThis extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …
Phase: PHASE3 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New bispecific antibody D3L-002 enters first human trial for Hard-to-Treat cancers
Disease control Not yet recruitingThis Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…
Phase: PHASE1 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental T-Cell therapy takes on advanced cancers
Disease control Not yet recruitingThis early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check …
Phase: EARLY_PHASE1 • Sponsor: Beijing Geekgene Technology Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail aims to shrink Hard-to-Treat tumors
Disease control Not yet recruitingThis study tests a new drug called LM-168 combined with other cancer treatments (tislelizumab or docetaxel) in 108 adults with advanced solid tumors. The first part finds a safe dose; the second part checks if the combination shrinks tumors. It is not yet recruiting.
Phase: PHASE2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could simple Over-the-Counter drugs supercharge cancer immunotherapy?
Disease control Not yet recruitingThis study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…
Phase: PHASE2 • Sponsor: Val Adams • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New cancer drug LNF2105 enters first human trials
Disease control Not yet recruitingThis early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…
Phase: PHASE1 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Experimental injection trains immune cells inside the body to fight cancer
Disease control Not yet recruitingThis early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…
Phase: PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug CS5007 targets tough cancers in first human trial
Disease control Not yet recruitingThis early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …
Phase: PHASE1 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…
Phase: PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets tough cancers with KRas G12V mutation
Disease control Not yet recruitingThis early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…
Phase: PHASE1 • Sponsor: Clasp Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New Antibody-Drug conjugate enters early human trials for advanced cancers
Disease control Not yet recruitingThis Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.
Phase: PHASE1 • Sponsor: Mabsoft Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug aims to boost red blood cells after transplant
Disease control Not yet recruitingThis study compares luspatercept to epoetin for patients with blood cancers who have poor red blood cell recovery after a stem cell transplant. About 90 adults will receive either drug every three weeks for 24 weeks. The goal is to see which treatment better reduces the need for …
Phase: PHASE2, PHASE3 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New injection YKYY031 enters human testing for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …
Phase: PHASE1 • Sponsor: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug targets hard-to-treat cancers in early trial
Disease control Not yet recruitingThis study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…
Phase: PHASE2 • Sponsor: Haihua Yuan • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New combo aims to fix transfusion failure in blood cancer patients
Disease control Not yet recruitingThis phase 3 trial tests whether acalabrutinib (a BTK inhibitor) alone or with bortezomib can lower harmful HLA antibodies that cause platelet transfusions to fail in blood cancer patients. About 42 adults with platelet transfusion refractoriness and high antibody levels will be …
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for kids with resistant cancers: targeted drug enters trial
Disease control Not yet recruitingThis study tests a drug called ifinatamab deruxtecan (I-DXd) in children with solid tumors that have returned or not responded to treatment. The drug is an antibody-drug conjugate that targets cancer cells directly. The trial aims to check safety and see if tumors shrink in about…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New pill takes on advanced cancers in first human test
Disease control Not yet recruitingThis early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…
Phase: PHASE1 • Sponsor: Groovy Medicine (Hangzhou) Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New antibody drug aims to outsmart tumors by targeting two immune pathways
Disease control Not yet recruitingThis study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …
Phase: PHASE1, PHASE2 • Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New pill targets hard-to-treat cancers with KRAS G12D mutation
Disease control Not yet recruitingThis early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…
Phase: PHASE1 • Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for advanced cancer patients as experimental drug enters trials
Disease control Not yet recruitingThis study tests a new drug called ICP-B208 in about 539 people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. Participants must be 18-75, have failed pr…
Phase: PHASE1, PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cancer drug QLC5508 enters first human safety tests
Disease control Not yet recruitingThis early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…
Phase: PHASE1, PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immune cell therapy takes on advanced cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …
Phase: EARLY_PHASE1 • Sponsor: Peking University Shenzhen Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cancer drug Hemay5087 enters first human tests
Disease control Not yet recruitingThis early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…
Phase: PHASE1 • Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cancer drug HH160 enters first human tests for advanced tumors
Disease control Not yet recruitingThis early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…
Phase: PHASE1 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for Hard-to-Treat cancers: drug targets MTAP deletion
Disease control Not yet recruitingThis phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New injection targets cancer fluid in lungs and belly
Disease control Not yet recruitingThis early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…
Phase: PHASE1 • Sponsor: WestVac Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo drug trial hopes to shrink Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.
Phase: PHASE1, PHASE2 • Sponsor: Convalife (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug CS231295 enters first human trial for tough cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …
Phase: PHASE1 • Sponsor: ThalassaX Therapeutics United States Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new drug, BI 1831169, combined with an existing immunotherapy (nivolumab) in Japanese adults with advanced solid tumors that have spread or not responded to prior treatments. The main goal is to find a safe, tolerable dose. Up to 46 participants wil…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New injection shows promise for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…
Phase: PHASE1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug IDP-001 takes on advanced cancers in early trial
Disease control Not yet recruitingThis study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…
Phase: PHASE1, PHASE2 • Sponsor: InduPro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New liposome drug takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…
Phase: PHASE1 • Sponsor: HighField Biopharmaceuticals Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug IN10028 tested for advanced cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…
Phase: PHASE1 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New program aims to protect hearts of breast cancer survivors
Disease control Not yet recruitingThis small pilot study will test a program where nurses and general practitioners help breast cancer survivors who also have heart disease make healthy lifestyle changes. The program includes exercise, diet changes, quitting smoking, and stress-reducing activities like yoga. The …
Phase: NA • Sponsor: University of Southern Queensland • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Robotic liver surgery from afar: a new frontier in surgical care?
Disease control Not yet recruitingThis study compares remote robotic liver surgery to local robotic surgery to see if the remote approach is just as safe and effective. About 148 adults with liver disease will be randomly assigned to one of the two types of surgery. Researchers will track complications, recovery,…
Phase: NA • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug may shield heart surgery patients from deadly complications
Disease control Not yet recruitingThis study tests whether the drug vericiguat can prevent serious heart and organ problems in people undergoing heart surgery. About 600 high-risk patients will receive either vericiguat plus standard care or standard care alone. The goal is to see if vericiguat reduces early comp…
Phase: NA • Sponsor: Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug 'Unmasks' cancer cells to immune system in early trial
Disease control Not yet recruitingThis early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New Dual-Targeting antibody enters human trials for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…
Phase: PHASE1 • Sponsor: Biotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug SKB118 aims to shrink Hard-to-Treat tumors
Disease control Not yet recruitingThis study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could early antibiotic stop be safe for kids with cancer?
Disease control Not yet recruitingThis trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…
Phase: PHASE4 • Sponsor: Hospital Universitari Vall d'Hebron Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug SYS6051 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.
Phase: PHASE1 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could less chemo be better after stem cell transplants?
Disease control Not yet recruitingThis phase 3 trial tests whether a lower dose of the chemotherapy drug cyclophosphamide can reduce side effects after a half-matched stem cell transplant for blood cancers. The standard dose often causes complications, so researchers want to see if a lower dose works just as well…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug SKB565 aims to fight advanced solid tumors
Disease control Not yet recruitingThis study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New Shot-in-the-Skin cancer drug tested in Real-World patients
Disease control Not yet recruitingThis study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …
Sponsor: IR INNOVATE RESEARCH PRIVATE LIMITED • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug FXB0871 takes on advanced cancers in first human trial
Disease control Not yet recruitingThis early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…
Phase: PHASE1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Can engineered red blood cells fight cancer? new trial launches
Disease control Not yet recruitingThis early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…
Phase: EARLY_PHASE1 • Sponsor: Zhejiang Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug KIVU-305 takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…
Phase: PHASE1 • Sponsor: Kivu Bioscience Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Snake venom protein tested as cancer treatment in humans
Disease control Not yet recruitingThis early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…
Phase: PHASE1 • Sponsor: Celtic Biotech Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for advanced cancer: ALK-N001 enters human trials
Disease control Not yet recruitingThis study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…
Phase: PHASE1, PHASE2 • Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for advanced cancer patients? early trial of ZE94-0605 begins
Disease control Not yet recruitingThis early-phase study tests an experimental drug called ZE94-0605 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any signs of tumor shrinkage. The study is not yet recruiting.
Phase: PHASE1 • Sponsor: Eilean Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New stitch and glue combo aims to cut infections after bypass surgery
Disease control Not yet recruitingThis study tests a new method for closing the breastbone after coronary artery bypass graft (CABG) surgery using special knotless barbed sutures and a skin adhesive. Researchers will compare 401 adults who receive this new closure to past patients who had standard closure. The go…
Phase: PHASE4 • Sponsor: Unity Health Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New cancer drug targets HER3 in advanced tumors
Disease control Not yet recruitingThis study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …
Phase: PHASE1, PHASE2 • Sponsor: Chengdu Kanghong Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New taxane drug RP-001 enters human trials for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …
Phase: PHASE1, PHASE2 • Sponsor: Recurv Pharma Inc • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug combo aims to shrink Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests an experimental drug called LRK-4189, given alone or with standard chemotherapy, for adults with advanced solid tumors that have not responded to prior treatment. The main goal is to check the drug's safety and find the best dose. About 120 participants will take…
Phase: PHASE1, PHASE2 • Sponsor: LARKSPUR BIOSCIENCES, INC. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a common parasite drug boost cancer immunotherapy?
Disease control Not yet recruitingThis study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…
Phase: PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New cancer drug SIG001 enters first human tests
Disease control Not yet recruitingThis early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for si…
Phase: PHASE1 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for rare blood vessel disorders: everolimus trial launches
Disease control Not yet recruitingThis phase 2 trial tests the drug everolimus in 67 people with vascular anomalies (abnormal blood vessels) that haven't responded to standard treatments. The goal is to shrink the lesions and improve symptoms. Participants take everolimus daily for 6 months, with doses adjusted b…
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New pill targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingThis study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…
Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug targets stomach and pancreatic cancers in early trial
Disease control Not yet recruitingThis study tests a new drug called LCB02A for people with advanced solid tumors that have a specific marker (CLDN18.2) and haven't responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, finding the safe…
Phase: PHASE1, PHASE2 • Sponsor: LigaChem Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug QLS5308 enters human testing for advanced cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo targets advanced cancers in early trial
Disease control Not yet recruitingThis study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…
Phase: PHASE1, PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New drug may cut transfusions for stem cell transplant patients
Disease control Not yet recruitingThis study tests if luspatercept can help people with blood cancers who have severe anemia after a stem cell transplant. The goal is to see if the drug reduces the need for red blood cell transfusions. About 20 adults aged 18-60 will take part. This is a phase 2 trial, meaning it…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New CAR-T therapy targets antibodies blocking Life-Saving transplants
Disease control Not yet recruitingThis early-stage study tests a new treatment using special immune cells (CAR-T cells) designed to reduce harmful antibodies that can prevent or damage bone marrow transplants. About 18 people with blood diseases who have these antibodies will receive the cells in increasing doses…
Phase: PHASE1, PHASE2 • Sponsor: Chang Yingjun • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Cord blood hope for elderly blood cancer patients
Disease control Not yet recruitingThis study tests a special chemotherapy combination followed by a single umbilical cord blood transplant in 44 patients aged 60-69 with blood cancers. The goal is to see if this approach is safe and reduces the risk of cancer returning within 180 days. Participants receive severa…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Specialist dream team takes on heart disease and diabetes
Disease control Not yet recruitingThis study tests whether a special clinic where heart, kidney, diabetes, and liver doctors work together can help people with type 2 diabetes and heart disease get better control of their blood pressure and cholesterol. About 150 adults will be randomly assigned to either usual c…
Phase: NA • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug T320 targets tough tumors in early trial
Disease control Not yet recruitingThis early-stage study tests a new drug called T320 in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive T320 every two wee…
Phase: PHASE1 • Sponsor: Nanolattix Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Engineered t cells take on Hard-to-Treat cancers in new trial
Disease control Not yet recruitingThis early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Engineered macrophages take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the bes…
Phase: EARLY_PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New cell therapy aims to train immune system against hard-to-treat cancers
Disease control Not yet recruitingThis early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Community exercise program aims to boost health in older adults with multiple chronic conditions
Disease control Not yet recruitingThis study tests a community-based exercise program for people aged 50 and older who have at least two chronic conditions, such as heart disease, diabetes, arthritis, or obesity. The program is designed to improve muscle strength, heart and lung fitness, and overall well-being. R…
Phase: NA • Sponsor: Associação para o Desenvolvimento do Centro Académico de Investigação e Formação Biomédica do Algarv • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug QLS5316 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New CAR t cell therapy targets tough childhood cancers in early trial
Disease control Not yet recruitingThis early-phase study tests whether a new cell therapy called B7-H3 CAR T cells is safe and can help children and young adults whose solid tumors have returned or stopped responding to standard treatments. About 40 participants will receive their own immune cells that have been …
Phase: PHASE1 • Sponsor: Robbie Majzner • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Microtransplantation: a new hope for advanced cancer patients?
Disease control Not yet recruitingThis early-stage trial tests a procedure called microtransplantation (MST) combined with chemotherapy in 10 adults with advanced or relapsed solid tumors. The goal is to see if MST can help control the disease and improve recovery of blood cells after chemo. The study focuses on …
Phase: PHASE1 • Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can a smart thermometer protect kids on chemo from dangerous fevers?
Disease control Not yet recruitingThis study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …
Phase: NA • Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Personalized cell therapy takes on Hard-to-Treat tumors
Disease control Not yet recruitingThis early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…
Phase: PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Supercharged T-Cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a new therapy called TCR-T cells, which are immune cells engineered to recognize and attack cancer cells with specific KRAS mutations (G12V or G12D). The study will enroll 25 adults with advanced solid tumors (like colorectal or lung cancer) who have …
Phase: EARLY_PHASE1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Vitamin b trial aims to cut heart surgery risks
Disease control Not yet recruitingThis study tests whether taking vitamin B supplements before and after heart surgery can lower the chance of serious problems like heart attack, stroke, or irregular heartbeat. About 1,000 adults having heart surgery will take either vitamin B or a placebo daily for 6 months afte…
Phase: NA • Sponsor: Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug FXS887 enters first human tests for tough cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…
Phase: PHASE1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New cancer drug HX111 enters early human trials
Disease control Not yet recruitingThis study tests a new drug, HX111, in about 70 people with advanced solid tumors or lymphoma that has not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and side eff…
Phase: PHASE1, PHASE2 • Sponsor: Hanx Biopharmaceuticals (Wuhan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New combo aims to fix Chemo-Caused low platelets
Disease control Not yet recruitingThis Phase 2 trial tests whether combining two platelet-boosting drugs (hetrombopag and rhTPO) works better than hetrombopag alone for cancer patients with dangerously low platelets from treatment. About 204 adults with solid tumors will be randomly assigned to one of the two gro…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Could a feeding tube after transplant save the gut?
Disease control Not yet recruitingThis study tests whether starting tube feeding right after a stem cell transplant can reduce severe gut graft-versus-host disease (GVHD) in people with blood cancers or disorders. About 112 participants will be randomly assigned to either standard care or early tube feeding. The …
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New pill takes on advanced cancers in early human trial
Disease control Not yet recruitingThis study tests an experimental oral drug called XNW34017 in 150 people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors. It is an…
Phase: PHASE1, PHASE2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Can a smartwatch make virtual heart rehab work better?
Disease control Not yet recruitingThis study looks at whether a medical-grade smartwatch (CardioWatch 287-2) can improve a 13-week virtual cardiac rehab program for people with heart disease. About 216 participants will either use the watch or not, and researchers will compare their progress in areas like exercis…
Phase: NA • Sponsor: Nova Scotia Health Authority • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Can a new pill tame immunotherapy's worst side effects and let patients restart treatment?
Disease control Not yet recruitingThis study tests a drug called ivarmacitinib in 72 people with advanced solid tumors who had to stop their cancer immunotherapy because of severe immune-related side effects. The goal is to see if the drug can control those side effects and, if successful, allow patients to safel…
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for rare cancers: china launches massive drug trial
Disease control Not yet recruitingThis study tests several new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants will receive treatments matched to their tumor's unique genetic profile. The goal is to see if these therapies are safe and shr…
Phase: PHASE1, PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for adults with advanced solid tumors that no longer respond to standard therapies. The main goal is to check safety, an…
Phase: PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New pill targets cancer growth pathway in advanced tumors
Disease control Not yet recruitingThis study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…
Phase: PHASE1, PHASE2 • Sponsor: TYK Medicines, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Can the RSV vaccine protect the most vulnerable? new study aims to find out
Disease control Not yet recruitingThis study tests whether the RSV vaccine Abrysvo can help blood cancer patients who have had a stem cell transplant or CAR-T therapy build immunity against RSV. Researchers will measure antibody levels before and after vaccination in 30 adults. The goal is to see if the vaccine t…
Phase: PHASE4 • Sponsor: The Cooper Health System • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New gene therapy trial hopes to tame advanced cancers
Disease control Not yet recruitingThis early-stage study tests a new treatment called KXV01 TCR Lentinvivo in 30 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. The treatment uses a virus to deliver cancer-fighting genes in…
Phase: PHASE1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New cancer pill enters first human tests
Disease control Not yet recruitingThis early-phase trial tests an experimental drug called ISM5939, taken as a pill, in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with chemotherapy (cisplatin or doce…
Phase: PHASE1 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Mushroom-Derived compound joins forces with radiation and immunotherapy to fight advanced cancers
Disease control Not yet recruitingThis phase 2 trial tests a combination of PRaG-1 Cordycepin Tablets (from a fungus), radiation therapy, immune-boosting injections, and immunotherapy drugs in 65 adults with advanced solid tumors who have no standard treatment options. The goal is to see if this mix improves immu…
Phase: PHASE2 • Sponsor: Second Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New stem cell transplant could help more blood cancer patients find a donor
Disease control Not yet recruitingThis study tests a new way to do stem cell transplants for adults with high-risk blood cancers who don't have a fully matched donor. Doctors will use stem cells from a half-matched (haploidentical) donor and remove certain immune cells to try to prevent severe graft-versus-host d…
Phase: NA • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could cutting vitamin B6 boost cancer immunotherapy?
Disease control Not yet recruitingThis early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New pill hopes to fight multiple cancers when other treatments fail
Disease control Not yet recruitingThis early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…
Phase: PHASE1 • Sponsor: AccSalus Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for tough cancers: experimental drug TB511 enters human trials
Disease control Not yet recruitingThis early-phase trial tests a new drug called TB511 in people with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that have stopped responding to standard care. The study has two parts: first, finding the safest dose of TB511 alone; second, testing TB511 com…
Phase: PHASE1, PHASE2 • Sponsor: Twinpig Biolab, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New mRNA vaccine takes on advanced cancers in early trial
Disease control Not yet recruitingThis study tests a new mRNA vaccine designed to help the immune system attack cancer cells. The vaccine targets a protein found only in tumors and is given together with an immunotherapy drug (anti-PD-1). About 60 adults with advanced solid tumors that cannot be removed by surger…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New radioactive 'Theranostic' drugs aim to find and treat brain tumors
Disease control Not yet recruitingThis study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…
Phase: PHASE2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New gene therapy trial hopes to fight Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called KXV01 TCR Lentinvivo for people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the right dose. About 30 adults aged 18 to 70 will take part, and researchers …
Phase: PHASE1 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug ATB-320 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…
Phase: PHASE1 • Sponsor: Autotelicbio • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Not yet recruitingThis study tests an experimental oral drug called GFH276 in people with advanced solid tumors that have RAS mutations, including pancreatic, lung, and colorectal cancers. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks if the drug shrinks tumors. About …
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Custom immune attack: new gene therapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a personalized gene therapy called KXV01 TCR Lentinvivo Injection for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a virus to deliver cancer-fighting genes into the patient's own immune cells. The …
Phase: PHASE1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Cancer drug RVU120 gets extended trial for ongoing patients
Disease control Not yet recruitingThis study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…
Phase: PHASE2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug aims to fix Chemo-Induced low platelets
Disease control Not yet recruitingThis study tests a drug called Romiplostim N01 in 106 cancer patients whose platelets drop due to chemo, radiation, or immunotherapy. The goal is to see if it can safely raise platelet counts better than the current standard treatment. Patients will be randomly assigned to receiv…
Phase: NA • Sponsor: Jun wang • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can a digital dispenser solve the pill problem for patients with multiple diseases?
Disease control Not yet recruitingThis study tests Mobili®, a portable digital dispenser that automatically gives the right pills at the right time. Researchers will enroll 96 adults with diabetes or heart disease who take at least two daily medications. Participants use the device for a period, and the study mea…
Phase: NA • Sponsor: Lusofona University • Aim: Disease control
Last updated Jun 26, 2026 17:49 UTC
-
New drug combo aims to fight Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial is testing a combination of two experimental drugs, IMM2510 and IMM01, in about 104 people with advanced solid tumors that have already been treated. The goal is to find safe doses and see if the combination can shrink tumors. The study is not yet recruitin…
Phase: PHASE1, PHASE2 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Jun 26, 2026 15:39 UTC
-
New combo therapy aims to tackle Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…
Phase: PHASE1, PHASE2 • Sponsor: Convalife (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 14:20 UTC
-
New hope for cancer patients: drug may fix Radiation-Related low platelets
Disease control Not yet recruitingThis phase 2 trial tests whether romiplostim N01 can safely raise low platelet counts in 60 adults with solid tumors who have had radiotherapy combined with other treatments. The main goal is to see if platelet counts increase by at least 50 billion per liter within two weeks. Th…
Phase: PHASE2 • Sponsor: Zhujiang Hospital • Aim: Disease control
Last updated Jun 26, 2026 14:03 UTC
-
New scan could spot hidden scarring in heart and lungs before It's too late
Diagnosis Not yet recruitingThis study tests a new radioactive tracer called 18F-FAPI-74 that may help detect scar tissue (fibrosis) in the heart and lungs earlier than current methods. Researchers will compare this new PET/CT scan to standard imaging in 210 adults with conditions like lung disease or heart…
Phase: PHASE3 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
New Dual-Targeted PET scan aims to spot cancers more clearly
Diagnosis Not yet recruitingThis study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…
Phase: NA • Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
New 'Smart' PET scan could spot hidden cancers
Diagnosis Not yet recruitingThis study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…
Phase: NA • Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Blood test breakthrough could speed up fungal lung infection diagnosis
Diagnosis Not yet recruitingThis study aims to see if a new blood test (mNGS) can accurately diagnose invasive fungal lung infections in 1,000 people with blood disorders. Participants will provide a blood sample and undergo standard tests, then be followed for 42 days. The goal is to find a faster, more re…
Sponsor: Peking University People's Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:06 UTC
-
New blood test method for liver disease could make diagnosis easier
Diagnosis Not yet recruitingThis study checks if a simpler way to collect blood samples works as well as the standard method for the HepQuant DuO liver test. The test involves drinking a natural substance and taking blood samples 20 and 60 minutes later. Researchers will compare different blood collection t…
Sponsor: HepQuant, LLC • Aim: Diagnosis
Last updated Jun 27, 2026 11:02 UTC
-
Could a simple scan replace biopsies for cancer immunotherapy?
Diagnosis Not yet recruitingThis study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 09:10 UTC
-
Could a simple scan prevent deadly liver failure after surgery?
Diagnosis Not yet recruitingThis study tests a special imaging scan (Tc-GSA SPECT/CT) to see if it can predict liver failure after surgery for liver tumors. About 192 adults in Denmark will receive the scan before their operation. The goal is to compare this new method with standard tests and find the best …
Phase: PHASE4 • Sponsor: Rigshospitalet, Denmark • Aim: Diagnosis
Last updated Jun 27, 2026 08:13 UTC
-
New trial aims to slash deadly bloodstream infections from hospital tubes
Prevention Not yet recruitingThis study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…
Phase: NA • Sponsor: The University of Queensland • Aim: Prevention
Last updated Jun 27, 2026 12:33 UTC
-
Glutamine supplement may shield kids from chemo nerve pain
Prevention Not yet recruitingThis study tests whether the supplement glutamine can prevent nerve damage caused by the chemotherapy drug vincristine in children and teens with cancer. About 70 participants, aged 6 to 18, will take glutamine twice daily for 14 days during their treatment. Researchers will trac…
Phase: PHASE3 • Sponsor: Ain Shams University • Aim: Prevention
Last updated Jun 27, 2026 08:04 UTC
-
Healing sounds and virtual worlds may replace sedatives in heart cath labs
Symptom relief Not yet recruitingThis pilot study explores whether non-drug strategies like virtual reality or relaxing soundscapes can reduce anxiety and pain in adults undergoing scheduled coronary angiography or angioplasty. Participants will be assigned to listen to calming sounds, experience a virtual reali…
Phase: NA • Sponsor: Olivier F. Bertrand • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
Timing your meals might ease cancer treatment side effects
Symptom relief Not yet recruitingThis study tests if eating only within an 8-hour window each day (time-restricted eating) can reduce treatment side effects and improve quality of life for people with solid tumors starting adjuvant therapy after surgery. Fifty adults will be randomly assigned to follow this eati…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Can a high fiber diet ease transplant recovery?
Symptom relief Not yet recruitingThis pilot study tests whether a dietitian-led High Fiber Program can help patients increase their fiber intake after receiving a stem cell transplant from a donor. The goal is to improve gut health and possibly reduce complications like graft-versus-host disease. About 44 adults…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
Magic mushroom compound tested for cancer pain relief
Symptom relief Not yet recruitingThis phase II trial tests whether low-dose psilocybin, a compound from magic mushrooms, combined with psychotherapy is safe and effective for easing chronic pain in cancer patients who already take opioids. Twenty adults with active cancer and moderate to severe pain will receive…
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Could a cannabis gummy be the key to better sleep for cancer patients?
Symptom relief Not yet recruitingThis study tests whether a cannabis gummy can improve sleep and quality of life in 50 cancer patients who have trouble sleeping. Participants will either take the gummy or receive usual care for 5 weeks. The goal is to see if the gummy is safe and helps with sleep, while also che…
Phase: PHASE1, PHASE2 • Sponsor: Theodore Brasky PhD • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Can talking about meaning help stem cell transplant recovery?
Symptom relief Not yet recruitingThis study tests whether a seven-session, telehealth-based therapy called Meaning-Centered Psychotherapy is practical and helpful for stem cell transplant survivors and their main caregivers. The program aims to help dyads stay connected to meaning, cope with difficult experience…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Ice chips vs. mouth sores: simple trick may ease chemo side effect
Symptom relief Not yet recruitingThis study tests whether sucking on ice chips during chemotherapy can prevent or reduce the severity of painful mouth sores (oral mucositis) in cancer patients. 102 adults receiving 5-fluorouracil or methotrexate will be randomly assigned to either get ice chips during infusion p…
Phase: NA • Sponsor: University of Health Sciences Lahore • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Dance away chemo pain: new study tests fun exercise for nerve damage
Symptom relief Not yet recruitingThis study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Robot dog brings joy to kids battling blood cancer
Symptom relief Not yet recruitingThis study tests whether a robotic dog named AIBO can improve emotional well-being and quality of life in children aged 8-15 with blood cancers who are undergoing a stem cell transplant. The children will interact with AIBO while isolated in the hospital for about 30 days. Resear…
Phase: NA • Sponsor: Koç University • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
No opioids, less confusion? new study for seniors having gut surgery
Symptom relief Not yet recruitingThis study looks at whether using a drug combination without opioids during anesthesia can lower the chance of confusion (delirium) after surgery in people 65 and older having gastrointestinal surgery. About 174 participants will be randomly assigned to receive either opioid-free…
Phase: PHASE1 • Sponsor: Qianfoshan Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Sound waves for better sleep: new trial tests ultrasound on heart patients
Symptom relief Not yet recruitingThis study tests whether low-intensity focused ultrasound (LIFU) applied to a nerve cluster in the neck can improve sleep quality and heart rate control in people recovering from heart surgery. 200 participants will receive either real or sham ultrasound daily for 3-7 days after …
Phase: NA • Sponsor: Renmin Hospital of Wuhan University • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Could a common numbing drug replace opioids after liver surgery?
Symptom relief Not yet recruitingThis study tests whether giving lidocaine through a vein during and after liver surgery can reduce side effects like nausea, vomiting, and breathing problems caused by opioid painkillers. About 312 adults having planned open liver surgery will be randomly assigned to receive eith…
Phase: PHASE4 • Sponsor: Rennes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Simple exercises may soothe chemo nerve damage
Symptom relief Not yet recruitingThis study tests whether a 15-minute hand and foot exercise routine can reduce nerve pain caused by Taxane chemotherapy in cancer patients. Fifty-eight adults with mild nerve symptoms will either do the exercises plus standard care or receive standard care alone. Researchers will…
Phase: NA • Sponsor: University of Health Sciences Lahore • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Miracle fruit may bring back taste for cancer patients
Symptom relief Not yet recruitingThis pilot study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in people with solid tumors undergoing cancer treatment. About 45 adults will take one mini-square before each meal for 90 days. The goal is to see if this simple supplement can ease a…
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
Painting away fatigue: art therapy trial for blood cancer patients
Symptom relief Not yet recruitingThis study tests whether doing art activities (like drawing or painting) can reduce fatigue, anxiety, and improve quality of life in adults with blood cancers. Fifty-two patients will be split into two groups: one gets six art sessions over two weeks, the other gets standard care…
Phase: NA • Sponsor: Gazi University • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Can acupuncture needles Kick-Start a paralyzed stomach after cancer surgery?
Symptom relief Not yet recruitingThis study tests whether electroacupuncture (mild electrical pulses through thin needles) can help patients whose stomachs stop working properly after surgery for digestive tract tumors. Seventy-six adults who had such surgery and developed gastroparesis (stomach paralysis) will …
Phase: NA • Sponsor: First Teaching Hospital of Tianjin University of Traditional Chinese Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Can a daily supplement calm your mind and heart?
Symptom relief Not yet recruitingThis study looks at whether a supplement called Neurofast® can help people who have both anxiety and heart problems. 80 adults aged 18-70 will take the supplement or no extra treatment for 12 weeks. Researchers will measure changes in anxiety, heart rate, and blood pressure.
Phase: NA • Sponsor: Liaquat University of Medical & Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Herbal soak may soothe Chemo's painful side effects
Symptom relief Not yet recruitingThis study tests whether a traditional Chinese medicine hand-foot soak can reduce nerve pain and skin reactions caused by chemotherapy. About 300 adults with solid tumors who have these side effects will use the soak. The goal is to see if it improves symptoms and quality of life…
Sponsor: Peking University Third Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Meditation boosts heart rehab: new study tests 15-Minute mindfulness fix
Symptom relief Not yet recruitingThis study tests whether adding a short, guided mindfulness meditation session to standard cardiac rehabilitation can help heart patients feel better and control their blood pressure. Eighty adults with heart disease will be split into two groups: one gets standard rehab plus med…
Phase: NA • Sponsor: Instituto Dante Pazzanese de Cardiologia • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
Can cannabis replace opioids for pain? new study aims to find out
Symptom relief Not yet recruitingThis study will compare cannabis, opioids, and two non-drug therapies (MIRE and TENS) in 1,000 people with chronic pain or circulatory disorders. The goal is to find safer, less addictive pain relief options. Researchers will measure changes in pain and nerve function using objec…
Phase: NA • Sponsor: American Association of Sensory Electrodiagnostic Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Can video calls replace clinic visits for palliative care?
Symptom relief Not yet recruitingThis study tests whether virtual palliative care (via video calls) works as well as standard in-person care for adults with cancer. About 252 participants will be randomly assigned to one of the two approaches. Researchers will measure quality of life, symptom burden, and satisfa…
Phase: NA • Sponsor: Al Al Bayt University, Jordan • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
4D MRI scans could reveal hidden clues about heart disease and cancer
Knowledge-focused Not yet recruitingThis study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…
Sponsor: Ulsan University Hospital • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Liver health may change how a promising cancer drug works in the body
Knowledge-focused Not yet recruitingThis study investigates how the experimental cancer drug atirmociclib is processed by the body in people with mild, moderate, or severe liver disease compared to those with healthy livers. Participants receive a single oral dose of the drug, and blood samples are taken over time …
Phase: PHASE1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Heart health advice misses the mark for ethnic minorities, study aims to find out why
Knowledge-focused Not yet recruitingThis study will interview 15 people from ethnic minority backgrounds in the UK who have heart disease. The goal is to understand their views on the diet and lifestyle advice they get from doctors, and whether it fits their cultural and religious customs. Researchers hope to learn…
Sponsor: University of Nottingham • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Could cousins be as good as siblings for stem cell donation?
Knowledge-focused Not yet recruitingThis study looks at whether using a cousin as a stem cell donor works as well as using a sibling for people with blood cancers. Researchers will compare survival, relapse, and side effects like graft-versus-host disease in patients who received a transplant from either a cousin o…
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Which ventilator mode is best for heart patients? a pilot study aims to find out
Knowledge-focused Not yet recruitingThis study tests whether it is possible to run a larger trial comparing two ways of using a breathing machine (ventilator) in critically ill heart patients who need help breathing. The two modes are volume-controlled (delivers a set amount of air each breath) and pressure-control…
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Heart Patients' hidden hurdles: new study probes barriers to psychosocial care
Knowledge-focused Not yet recruitingThis observational study at a French hospital will ask 20 heart rehab patients and their care teams about what stops them from getting or offering psychological and social support. The goal is to understand these barriers so that hospitals can better help patients return to work …
Sponsor: Centre Hospitalier Sud Francilien • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Liver health may change how body handles inhaled lung drug
Knowledge-focused Not yet recruitingThis phase 1 trial investigates how mild, moderate, and severe liver impairment affects the way the body processes a single inhaled dose of treprostinil palmitil, a drug used for certain lung conditions. The study enrolls about 30 adults with varying levels of liver function and …
Phase: PHASE1 • Sponsor: Insmed Incorporated • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Tracing a cancer Drug's journey through the body
Knowledge-focused Not yet recruitingThis study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New MRI methods could spot liver damage earlier
Knowledge-focused Not yet recruitingThis study tests new MRI techniques to measure blood flow and tissue details in the liver. Researchers will scan 110 people, including healthy volunteers and those with chronic liver disease or fibrosis, to see if these scans can reliably detect liver damage. The goal is to devel…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New MRI shortcut could sharpen views of blood vessels
Knowledge-focused Not yet recruitingThis study aims to see if a quicker MRI scan can produce images of blood vessel walls that are just as good as the standard, longer scan. Researchers will enroll 15 adults who already need a vessel wall MRI as part of their care. The faster scan will be compared to the regular on…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
New obesity drug tested in people with liver problems
Knowledge-focused Not yet recruitingThis early-stage study is testing a new medicine for overweight and obesity. The main goal is to see how the drug behaves in people with different levels of liver function, from normal to severely reduced. About 35 adults aged 18-80 will take a single dose, and researchers will m…
Phase: PHASE1 • Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Lifestyle tweaks may cut liver cancer risk, new study hints
Knowledge-focused Not yet recruitingThis study looks at whether lifestyle changes can reduce the risk of liver cancer in people already at high risk. Researchers will track changes in bile acids, gut bacteria, and liver health in 90 adults aged 50-90. The goal is to see if simple adjustments can make a lasting diff…
Phase: NA • Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Does breakfast change how chemo works? new study investigates
Knowledge-focused Not yet recruitingThis early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…
Phase: PHASE1 • Sponsor: Health Hope Pharma • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Liver function study tests new Drug's safety in 24 volunteers
Knowledge-focused Not yet recruitingThis early-stage study looks at how a single 25 mg dose of VC005 tablets behaves in people with mild or moderate liver impairment compared to healthy volunteers. The goal is to measure drug levels and safety. 24 participants will take one dose and be monitored closely.
Phase: PHASE1 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
1,000 patients to help unlock secrets of liver surgery recovery
Knowledge-focused Not yet recruitingThis study will follow 1,000 adults who have liver or bile duct surgery at one hospital in Italy. Researchers will track complications, survival, and cancer recurrence for up to 5 years. The goal is to better understand what affects recovery and long-term health after these opera…
Sponsor: Azienda USL Toscana Centro • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Women-Only heart classes aim to boost recovery and knowledge
Knowledge-focused Not yet recruitingThis pilot study will test whether a women-focused education program, called Cardiac College for Women, helps women with heart disease learn more about their condition and feel better. About 50 women in cardiac rehab across Canada will either get the program plus usual care or us…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New liver safety study for experimental drug MDR-001 begins
Knowledge-focused Not yet recruitingThis early-stage study will give a single dose of MDR-001, a GLP-1 receptor agonist tablet, to 32 people: some with mild or moderate liver impairment and some with healthy livers. Researchers want to see how the drug moves through the body and if it is safe in people with liver i…
Phase: PHASE1 • Sponsor: MindRank AI Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Italian study to track Real-World use of Next-Gen cholesterol drugs
Knowledge-focused Not yet recruitingThis study will look at how consistently nearly 6,000 adults in Italy take three newer cholesterol-lowering drugs (inclisiran, evolocumab, and alirocumab) over the long term. Researchers will analyze prescription records to measure adherence and persistence in everyday medical pr…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Liver function may change how lung cancer drug works
Knowledge-focused Not yet recruitingThis early-stage study looks at how the drug anecatibin fumarate is processed in the body of people with and without liver problems. It will include 24 adults with lung cancer. The goal is to understand safety and drug levels, not to test if the drug works.
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Liver function and drug levels: a closer look at GS1-144
Knowledge-focused Not yet recruitingThis early-stage study looks at how the drug GS1-144 moves through the bodies of women with and without liver problems. About 24 women aged 18 to 70 will take part. The goal is to measure drug levels and see if liver function affects them. No treatment is being tested.
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Heart imaging revolution? 1000-Person study tests new MRI tech
Knowledge-focused Not yet recruitingThis study will test new MRI methods to find early signs of heart disease in 1000 adults. Researchers want to see if these scans can detect tiny changes in heart muscle before standard tests do. Participants will have MRI scans and blood work, but no treatment is given. The goal …
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Can a simple quiz spot frailty in older cancer patients?
Knowledge-focused Not yet recruitingThis study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…
Sponsor: Hospital de Braga • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Scientists hunt for biological clues to Cancer-Related anxiety and depression
Knowledge-focused Not yet recruitingThis study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…
Sponsor: The First Affiliated Hospital of Xinxiang Medical College • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Liver function may change how anxiety drug works
Knowledge-focused Not yet recruitingThis early-stage study looks at how the drug buagafuran (AF-5) behaves in people with liver impairment compared to those with normal liver function. Twenty-four adults will receive a single 30 mg dose, and researchers will measure drug levels in the blood and monitor safety. The …
Phase: PHASE1 • Sponsor: Beijing Union Pharmaceutical Factory Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
AI learns to read scans and reports for smarter disease diagnosis
Knowledge-focused Not yet recruitingThis study aims to create an artificial intelligence (AI) system that can combine medical images (like CT and MRI scans) with patient records and lab results to help doctors more accurately diagnose diseases of the liver, gallbladder, and pancreas. The researchers will use data f…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
New cancer trial aims to crack the code of who benefits from immunotherapy
Knowledge-focused Not yet recruitingThis study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Liver function and drug processing: a closer look at hydronidone
Knowledge-focused Not yet recruitingThis study looks at how the drug hydronidone moves through the body in people with different levels of liver function. Thirty adults with either normal liver function or varying degrees of liver impairment will take a single dose of the drug. The goal is to understand how liver h…
Phase: PHASE1 • Sponsor: Beijing Continent Pharmaceutical Co, Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Could new hormone creams protect menopausal Women's hearts?
Knowledge-focused Not yet recruitingThis large registry study will follow over 2,700 postmenopausal women aged 45-75 who use newer forms of hormone replacement therapy (creams, gels, sprays). The goal is to see if these modern delivery methods lower the risk of heart attacks, strokes, and other cardiovascular event…
Sponsor: Heinrich-Heine University, Duesseldorf • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
New study to uncover hidden risks for heart patients over 80 in the ICU
Knowledge-focused Not yet recruitingThis study will follow 4,000 intensive care patients aged 80 and older to see how chronic and acute heart conditions impact their survival, daily function, and quality of life. Researchers will use simple tests to measure frailty and independence. The goal is to help doctors bett…
Sponsor: Heinrich-Heine University, Duesseldorf • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
30,000 blood samples could revolutionize rapid disease testing
Knowledge-focused Not yet recruitingThis study will collect blood samples from 30,000 adults in the UK with various health conditions, including blood clots, infections, heart disease, diabetes, and more. The samples will be used to develop and fine-tune new diagnostic tests for the cobas® lumira device, which allo…
Sponsor: LumiraDx UK Limited • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
500 beijing seniors to be tracked for urinary health and disease links
Knowledge-focused Not yet recruitingThis study will follow 500 Beijing residents aged 60 and older to see how urinary function (like bladder and kidney health) relates to the development of multiple chronic conditions such as diabetes, heart disease, and Alzheimer's. Participants will have regular health checks, bl…
Sponsor: Chinese PLA General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
New study aims to uncover hidden liver risks in pregnant women
Knowledge-focused Not yet recruitingThis study will look at 80 pregnant women with signs of liver issues, such as high liver enzymes or bilirubin, to find out which liver disorders are most common and how they affect both mother and baby. Researchers will track changes in liver health over time using blood tests an…
Sponsor: Eman Ashraf Saad Ahmed • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Liver transplant showdown: auxiliary vs. living donor – which saves more lives?
Knowledge-focused Not yet recruitingThis study will compare two types of liver transplants: auxiliary (where part of the patient's own liver is left in place) and living donor (where a portion of a donor's liver is used). Researchers will track 100 patients to see which approach leads to better survival, fewer comp…
Sponsor: Zhi-Jun Zhu • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Heart clinic mental health crisis revealed?
Knowledge-focused Not yet recruitingThis study will ask 380 heart patients and healthcare workers at Assiut University Heart Hospital to fill out questionnaires about depression, anxiety, stress, and burnout. No treatments or changes are given—the goal is simply to find out how common these mental health problems a…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Liver disease study aims to map recovery and organ failure over 6 months
Knowledge-focused Not yet recruitingThis study will follow 100 adults with chronic liver disease who are hospitalized for sudden worsening of their condition. Researchers will track organ failure, recovery, and whether patients need a liver transplant or die within 6 months. The goal is to better understand how the…
Sponsor: Institute of Liver and Biliary Sciences, India • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
New test could predict immunotherapy success in blood cancers
Knowledge-focused Not yet recruitingThis study aims to develop a simple blood test that checks how well a person's immune cells can fight blood cancer. Researchers will collect blood samples from 166 adults with blood cancers to measure immune cell activity and look at genetic factors. The goal is to create a test …
Phase: NA • Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
New registry aims to decode mysterious immune side effects of cancer drugs
Knowledge-focused Not yet recruitingThis study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
New tool to measure Cancer's financial toll tested in turkey
Knowledge-focused Not yet recruitingThis study aims to adapt a questionnaire called PROFFIT, originally developed in Italy, to measure financial toxicity (the financial burden of cancer treatment) in Turkish patients. Researchers will enroll 320 adults with cancer who have received treatment in the last three month…
Sponsor: Akdeniz University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Gut check: could your microbiome predict fertility after immunotherapy?
Knowledge-focused Not yet recruitingThis observational study looks at how immune checkpoint inhibitors (a type of cancer immunotherapy) affect ovarian function and fertility in women aged 18-38 with solid tumors. Researchers will collect blood and stool samples before and during treatment to measure hormone levels …
Sponsor: West China Second University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
AI stethoscope could spot hidden heart disease early
Knowledge-focused Not yet recruitingThis study will test whether an artificial intelligence (AI) system can detect pulmonary hypertension and other heart diseases using a smart stethoscope. Researchers will collect heart sound and ECG recordings from 1,000 adults already scheduled for routine echocardiography. The …
Sponsor: Imperial College London • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Sleep troubles may worsen heart disease in seniors, new study warns
Knowledge-focused Not yet recruitingThis study looks at how sleep disorders and problems with the body's automatic functions (like heart rate control) are linked in elderly people with heart disease. Researchers will study 210 patients aged 65 and older to find out how common sleep issues are and how they affect he…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Real-world test of adebrelimab combo for tough cancers
Knowledge-focused Not yet recruitingThis study will observe 300 people with advanced lung or gastrointestinal cancers who receive adebrelimab combined with other treatments. Researchers will track side effects and how well the cancer responds. It is a real-world study, meaning it watches what happens in regular med…
Sponsor: Tianjin First Central Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:13 UTC
-
New blood test aims to predict who will respond to immunotherapy
Knowledge-focused Not yet recruitingThis study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100…
Phase: NA • Sponsor: Centre Leon Berard • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:54 UTC
-
New study to track hidden salt and mineral imbalances in sick kids
Knowledge-focused Not yet recruitingThis study will look at 150 infants and children aged 1 month to 4 years who are admitted to a hospital gastroenterology unit with a gastrointestinal disease. The goal is to find out how common electrolyte disturbances (like low sodium or potassium) are in these children. By meas…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:41 UTC